Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer

Model scores of the 29,894 trials active now.

Model score 23% for any early termination, 8% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 22% of the time (376 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2013-07-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: breast cancerher2metastaticreceptorradiation
  Phrases that lowered it: participantsparticipantdays before14 daystrial
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Sponsor's past termination rate: 12.2% (raises risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 293 (raises risk) · Sponsor's track record
• Has a data monitoring committee: not given (lowers risk) · Design
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Sponsor's past trials: 576 (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Sponsor type: government (raises risk) · Sponsor's track record
• Disease area, dermatology: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Tivantinib in Treating Patients With Metastatic Prostate Cancer NCT01519414 · started 2012 · scored riskier than 59% of active trials completed
• Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer NCT03054363 · started 2017 · scored riskier than 48% of active trials completed
• Trial to Evaluate Efficacy and Safety of Pembrolizumab and Gemcitabine in HER2-negative ABC NCT03025880 · started 2017 · scored riskier than 80% of active trials completed
• Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer NCT05583110 · started 2023 · scored riskier than 80% of active trials terminated
• PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer NCT02423603 · started 2014 · scored riskier than 89% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.